Publications by authors named "S E Lerner"
Article Synopsis
- Bladder cancer (BCa) presents a significant financial challenge for both healthcare systems and patients, necessitating an understanding of its economic impacts for better resource management and treatment effectiveness.
- A systematic review was performed following PRISMA guidelines to assess the financial implications of BCa, including various costs, cost effectiveness, and the phenomenon of financial toxicity (FT) across multiple studies.
- High-risk non-muscle-invasive BCa can lead to expenses over $200,000 within five years, while metastatic BCa presents the most financial strain, with treatment costs ranging wildly and disproportionately affecting younger, less-educated, and minority groups.
Background And Objective: Non-muscle-invasive bladder cancer (NMIBC) patients treated with additional bacillus Calmette-Guérin (BCG) may become unresponsive to BCG. Recently, sequential intravesical gemcitabine and docetaxel (gem/doce) are being used for NMIBC. This study aims to compare oncologic outcomes between sequential intravesical gem/doce versus additional BCG in patients with BCG-unresponsive NMIBC.
View Article and Find Full Text PDFBackground: Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder cancer undergoing radical cystectomy is unclear.
Methods: We randomly assigned, in a 1:1 ratio, patients with localized muscle-invasive bladder cancer of clinical stage T2 (confined to muscle) to T4a (invading adjacent organs) with two or fewer positive nodes (N0, N1, or N2) to undergo bilateral standard lymphadenectomy (dissection of lymph nodes on both sides of the pelvis) or extended lymphadenectomy involving removal of common iliac, presciatic, and presacral nodes. Randomization was performed during surgery and stratified according to the receipt and type of neoadjuvant chemotherapy, tumor stage (T2 vs.
Article Synopsis
- A study explored the relationship between body mass index (BMI) and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), finding that higher BMI may lead to better survival outcomes.
- Out of 1,279 patients analyzed from the SWOG-1216 trial, survival rates increased with higher BMI categories, with the median OS being longest in the obese group at 6.8 years.
- The analysis suggests that these findings, indicating a lower risk of death among patients with higher BMI, need further validation in additional clinical trials.
Article Synopsis
- * Researchers analyzed tumor samples from 179 patients and found 23% had harmful DDR gene alterations, which were linked to better pathologic responses after treatment.
- * The findings suggest that these DDR alterations could serve as potential biomarkers for predicting treatment response in bladder cancer patients receiving neoadjuvant chemotherapy.